Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature
Open Access
- 24 December 2019
- journal article
- review article
- Published by Springer Nature in Molecular Autism
- Vol. 10 (1) , 1-22
Abstract
Phelan-McDermid syndrome (PMS) is caused by haploinsufficiency of theSHANK3gene on chromosome 22q13.33 and is characterized by intellectual disability, hypotonia, severe speech impairments, and autism spectrum disorder. Emerging evidence indicates that there are changes over time in the phenotype observed in individuals with PMS, including severe neuropsychiatric symptoms and loss of skills occurring in adolescence and adulthood. To gain further insight into these phenomena and to better understand the long-term course of the disorder, we conducted a systematic literature review and identified 56 PMS cases showing signs of behavioral and neurologic decompensation in adolescence or adulthood (30 females, 25 males, 1 gender unknown). Clinical presentations included features of bipolar disorder, catatonia, psychosis, and loss of skills, occurring at a mean age of 20 years. There were no apparent sex differences in the rates of these disorders except for catatonia, which appeared to be more frequent in females (13 females, 3 males). Reports of individuals with point mutations inSHANK3exhibiting neuropsychiatric decompensation and loss of skills demonstrate that loss of one copy ofSHANK3is sufficient to cause these manifestations. In the majority of cases, no apparent cause could be identified; in others, symptoms appeared after acute events, such as infections, prolonged or particularly intense seizures, or changes in the individual’s environment. Several individuals had a progressive neurological deterioration, including one with juvenile onset metachromatic leukodystrophy, a severe demyelinating disorder caused by recessive mutations in theARSAgene in 22q13.33. These reports provide insights into treatment options that have proven helpful in some cases, and are reviewed herein. Our survey highlights how little is currently known about neuropsychiatric presentations and loss of skills in PMS and underscores the importance of studying the natural history in individuals with PMS, including both cross-sectional and long-term longitudinal analyses. Clearer delineation of these neuropsychiatric symptoms will contribute to their recognition and prompt management and will also help uncover the underlying biological mechanisms, potentially leading to improved interventions.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS105845-01)
- New York Community Trust Jules and Ethel Klein Fund ((none))
- Beatrice and Samuel A. Seaver Foundation ((none))
- NIH Rare Disease Clinical Research Network (1 U54 NS092090-01)
This publication has 75 references indexed in Scilit:
- Deletion of the last exon of SHANK3 gene produces the full Phelan–McDermid phenotype: A case reportGene, 2013
- Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiencyMolecular Autism, 2013
- SHANK3 haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disordersMolecular Autism, 2013
- High Proportion of 22q13 Deletions and SHANK3 Mutations in Chinese Patients with Intellectual DisabilityPLOS ONE, 2012
- Phelan-McDermid syndrome in two adult brothers: atypical bipolar disorder as its psychopathological phenotype?Neuropsychiatric Disease and Treatment, 2012
- Molecular Mechanisms Generating and Stabilizing Terminal 22q13 Deletions in 44 Subjects with Phelan/McDermid SyndromePLOS Genetics, 2011
- Ring chromosome 22 and neurofibromatosis type II: proof of two‐hit model for the loss of the NF2 gene in the development of meningiomaClinical Genetics, 2010
- Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndromeBrain and Development, 2010
- De novo mutations in the gene encoding the synaptic scaffolding proteinSHANK3in patients ascertained for schizophreniaProceedings of the National Academy of Sciences, 2010
- Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disordersNature Genetics, 2006